Dr. Josh Jang and colleagues on the Van Andel Institute – Stand Up To Cancer Epigenetics Dream Team are studying why, in very rare cases, some cancers progress more quickly after treatment with immunotherapy. They may have pinpointed a possible culprit: a molecular pathway called AHR. Thanks in part to a prestigious K99 award from the National Cancer Institute (NCI), Dr. Jang and his colleagues will investigate how AHR may drive this accelerated progression.
Van Andel Institute’s Post
More Relevant Posts
-
A booklet on lung cancer management, generally and on how can a ALK mutation be managed. Beneficial to the public to read and be aware about the condition. Kudos to National Cancer Society, Lung Cancer Network Malaysia and Pfizer. Link to the booklet https://lnkd.in/gwNGhpz7
-
-
CEO, Throughline | Board Director | Digital Transformation & Evolution | Future of Enterprise Design & Visual Communications
Important article about the rise in cancer cases among those under 50. "New cancer cases among the under 50s increased by 79% in 2019 compared to 1990 and that most of these cases and deaths were attributed to breast cancer," reports Sarah Whelan, PhD. This piece really highlights why we need to invest in cancer research. If we want to reduce these cancer rates, it's crucial that we understand what is causing this rise in cancer cases. #CancerCases #CancerResearch #CancerAwareness
Cancer Cases Surge in Under 50s Over the Last 3 Decades
technologynetworks.com
-
We are developing Nu.Q® Cancer - a range of blood-based tests - to detect characteristic epigenetic changes in nucleosomes that occur from the earliest stages of #cancer. Being able to use epigenetic information from the nucleosomes of tumor cells could help physicians predict treatment response, monitor disease progression, and take action early. Learn more: tinyurl.com/mrx93p39
Volition is currently investigating the potential use of Nu.Q® tests in a range of cancers and clinical settings.
https://volition.com
-
There is no shortage of innovation happening in the world of lung cancer. Coming off such notable conferences as the 2023 World Conference on Lung Cancer, ESMO Congress 2023, and The 18th Annual New York Lung Cancers Symposium, Lung Cancers Today with Fred R. Hirsch, MD, PhD, of Mount Sinai, about current and future lung cancer treatments and innovations that pique his interest. #lungcancer #healthtrends #lungcancerstoday Watch Now:
Dr. Fred Hirsch Discusses Recent, Exciting Advancements in Lung Cancer Therapy | Docwire News
-
IARC released a report on the major trends in cancer incidence and mortality around the world - Union for International Cancer Control (UICC) IARC - International Agency for Research on Cancer / World Health Organization Dr Cary Adams Isabelle Soerjomataram #Cancer #CancerMortality #CancerPodcast #CancerResearch #GlobalCancerBurden #IARC #OncoDaily #Oncology #UICC
IARC released a report on the major trends in cancer incidence and mortality around the world - UICC - OncoDaily
oncodaily.com
-
Today, is the #WorldLungCancerDay 🎗️🌍 World Lung Cancer Day is #August_1, 2023. Lung cancer continues to be one of the #most_common cancers worldwide, claiming more lives yearly than #breast, #colon and #prostate cancers combined. It is estimated that lung cancer accounts for nearly one in five cancer #deaths globally. In #2012, there were 1.8 million newly #diagnosed cases of lung cancer alone.
-
-
Worldwide Cancer Research is the newest member of Cancer52! Worldwide Cancer Research starts new cures by funding pioneering discovery research - from anywhere in the world, into any type of cancer. They back brand new ideas that could change the course of cancer research, and take us one step closer to a day when no life is cut short by cancer. We hope that future collaboration will highlight the need to fund more research into all cancers, including rare and less common cancers
-
-
🚀 ASCO 2024 Highlight: Dr Marika Rasschaert from University Hospital Antwerp shares key insights on head & neck cancer. Discover critical studies on nasopharyngeal cancer, HPV-positive oropharyngeal cancers and advanced irradiation methods. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #HeadAndNeckCancer #OncologyInnovation
-
Medical Student, The Ohio State University College of Medicine and Science Behind Science Podcast Host
Stetson manages a great substack that anyone should check out who is interested in cancer genetics and cutting-edge cancer therapies. Here, he writes about one of the most well-known genes in cancer to the general public: BRCA. Very useful information for more background on the history of cancer genetics and the biology behind how gene mutations can lead to disease!
In the spirit of Breast Cancer Awareness, I wrote a bit more about BRCA and hereditary breast and ovarian cancer (HBOC). Although there are no definitive answers, I wrote a bit about the organ-specific pattern of cancer risk in BRCA1/2 mutation carriers. If anyone is up-to-date on the latest and best research on this question, please share. I also sprinkled in a bit about multiplex assays of variant effect (MAVEs), citing the 2018 study of BRCA1. I think MAVE studies will provide important support to variant classification work in the near future. https://lnkd.in/gZ5XxKQB
-
-
Question: How does ECI® work? Answer: Cancer has many ways to hide from the patient’s immune system, which prevents the immune system from eliminating it. The ELIAS Cancer Immunotherapy (ECI®) works by stimulating the patient’s immune system to recognize cancer cells as “foreign” and subsequently eliminate them. #ELIAS #ECI #Cancer #CanineCancer #CancerTreatment #CureCancer
-
